Search research articles
Contact Us
Filters
Showing results (11-20 of 34) with videos related to
Page
of 4
Sort By:
Plos One
|
March 13, 2014
Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN)
Gregory L Price, Keith L Davis, Sudeep Karve, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 5, 2022
Outcomes for Patients With Chronic Lymphocytic Leukemia (CLL) Previously Treated With Both a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study
Anthony R Mato, Lisa M Hess, Yongmei Chen, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
July 28, 2018
LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial
Talia Golan, Ravit Geva, Donald Richards, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 31, 2013
Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET
Wenjuan Wu, Chen Bi, Kelly M Credille, et al.
Investigational New Drugs
|
December 1, 2017
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
S Betty Yan, Suzane L Um, Victoria L Peek, et al.
Plos One
|
February 26, 2009
Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis
Timothy A Graubert, Michelle A Payton, Jin Shao, et al.
Leukemia & Lymphoma
|
March 29, 2023
Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study
Toby A Eyre, Lisa M Hess, Tomoko Sugihara, et al.
The Oncologist
|
June 2, 2018
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)
Hendrik-Tobias Arkenau, Juan Martin-Liberal, Emiliano Calvo, et al.
Leukemia Research
|
September 22, 2017
A phase 1 study of the Janus kinase 2 (JAK2)<sup>V617F</sup> inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia
Srdan Verstovsek, Ruben A Mesa, Mohamed E Salama, et al.
American Journal of Hematology
|
August 4, 2009
A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes
Mike G Martin, Richard A Walgren, Elizabeth Procknow, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 34) with videos related to
Sort By:
Page
of 4
Plos One
|
March 13, 2014
Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN)
Gregory L Price, Keith L Davis, Sudeep Karve, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 5, 2022
Outcomes for Patients With Chronic Lymphocytic Leukemia (CLL) Previously Treated With Both a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study
Anthony R Mato, Lisa M Hess, Yongmei Chen, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
July 28, 2018
LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial
Talia Golan, Ravit Geva, Donald Richards, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 31, 2013
Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET
Wenjuan Wu, Chen Bi, Kelly M Credille, et al.
Investigational New Drugs
|
December 1, 2017
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
S Betty Yan, Suzane L Um, Victoria L Peek, et al.
Plos One
|
February 26, 2009
Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis
Timothy A Graubert, Michelle A Payton, Jin Shao, et al.
Leukemia & Lymphoma
|
March 29, 2023
Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study
Toby A Eyre, Lisa M Hess, Tomoko Sugihara, et al.
The Oncologist
|
June 2, 2018
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)
Hendrik-Tobias Arkenau, Juan Martin-Liberal, Emiliano Calvo, et al.
Leukemia Research
|
September 22, 2017
A phase 1 study of the Janus kinase 2 (JAK2)<sup>V617F</sup> inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia
Srdan Verstovsek, Ruben A Mesa, Mohamed E Salama, et al.
American Journal of Hematology
|
August 4, 2009
A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes
Mike G Martin, Richard A Walgren, Elizabeth Procknow, et al.
Page
of 4